Investor Relations

2013 News Releases

Webcast ImageWebcast
KemPharm Inc at the Oppenheimer & Co. 27th Annual Healthcare Conference (Replay)
03/21/17 at 9:45 a.m. ET
KemPharm Inc at the Oppenheimer & Co. 27th Annual Healthcare Conference
Tuesday, March 21, 2017 9:45 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/04/13KemPharm, Inc. to Present at Oppenheimer 24th Annual Healthcare Conference in New York City
Coralville, IA – December 4, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that president and CEO, Travis Mickle, Ph.D. will present at the Oppenheimer 24th Annual Healthcare Conference being held in New York City December 10-11, 2013. Among the topics to be discussed, Dr. Mickle will provide an overview of KP201, the company's lead clinical candidate in development for the treatme... 
Printer Friendly Version
11/01/13KemPharm Completes Successful End-of-Phase 2 Meeting with FDA
Clinical, Non-Clinical and CMC Development Programs on Track for Third Quarter 2014 NDA Submission North Liberty, IA – Nov. 1, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration (FDA) for its lead pain candidate, KP201 (benzhydrocodone hydrochloride and acetaminophen). Based on the results of th... 
Printer Friendly Version
10/23/13KemPharm Forms Physician Advisory Council Advocating "Intelligent Pain Therapeutic Development"
Pain Management Thought Leaders, Jeffrey A. Gudin, MD, and Srinivas Nalamachu, MD to Lead Council as Interest in Prodrug-Based Pain Therapeutics BuildsNorth Liberty, IA – October 23, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has formed a Physician Advisory Council and named renowned pain specialists, Jeffrey A. Gudin, MD, and Srinivas Nalamachu, MD, as its co-chairs. In... 
Printer Friendly Version
09/25/13KemPharm's KP201 Demonstrates Bioequivalence Compared to Norco® in Key Pivotal Clinical Study
Travis C. Mickle, Ph.D., President & CEO of KemPharm, to Present Results at The 7th Annual Pain Therapeutics Summit East North Liberty, IA and Boston, MA – Sept. 25, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, today announced results from a second pivotal clinical study of KP201 (benzhydrocodone hydrochloride and acetaminophen) in preparation for a New Drug Application (NDA) which the compan... 
Printer Friendly Version
09/04/13KemPharm Continues to Expand its Pain Therapy Pipeline with Discovery of KP606, a Novel Prodrug of Oxycodone
KP606 Introduced at PAINWeek 2013 North Liberty, IA and Las Vegas, NV – Sept. 4, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, today announced the advancement of a new pain therapy program, KP606, a first-in-class oral prodrug of oxycodone. KP606 adds to the Company's franchise of abuse-deterrent prodrugs, which includes KP201 (hydrocodone) and KP511 (hydromorphone).KemPharm announced the discover... 
Printer Friendly Version
08/28/13KemPharm's KP201 to be Featured at PAINWeek 2013
Poster Presentation to Highlight KP201's Unique Abuse-Deterrent Properties and Its Potential to Prevent or Reduce Opioid-Induced Constipation North Liberty, IA – Aug. 28, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will present a poster on KP201 at PAINWeek 2013, the nation's largest pain conference for frontline clinic... 
Printer Friendly Version
08/26/13KemPharm's KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
Clinical Study Also Indicates No Systemic Prodrug Exposure Over Multiple-Day Dosing at Maximum Daily Dose North Liberty, IA – August 26, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, today announced positive results from one of several clinical and non-clinical studies that the company is performing in preparation for its New Drug Application (NDA) for KP201 (benzhydrocodone and acetaminophen), wh... 
Printer Friendly Version
08/07/13 KemPharm, Inc. Receives Additional Notice of Allowance for Novel Prodrugs of Hydrocodone
North Liberty, IA – August 7, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled, "Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Method of Making and Use Thereof." The most recent Notice of Al... 
Printer Friendly Version
07/15/13KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
30-Year Investment Banking Veteran Joins KemPharm to Strengthen its Business & Financial OperationsNorth Liberty, IA – July 15, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the appointment of Gordon K. "Rusty" Johnson as Chief Operating Officer (COO) and Chief Financial Officer (CFO). As COO and CFO of KemPharm, Mr. Johnson will join KemPharm's executive management team and wi... 
Printer Friendly Version
06/11/13KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
North Liberty, IA – June 11, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,461,137 to KemPharm for its patent application entitled, "Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydrocodone, Prodrugs, Methods of Making and Use Thereof." The patent, which extend... 
Printer Friendly Version
06/04/13KemPharm's KP201 Featured at the International Conference on Opioids
Poster Presentation to Highlight KP201's Unique Abuse-Deterrent Properties and Its Potential to Prevent or Reduce Opioid-Induced Constipation North Liberty, IA – June 4, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that that its Vice President of Research, Sven Guenther, Ph.D., will present a poster on the Company's novel pain drug candidate, KP201, at the International Conference... 
Printer Friendly Version
04/03/13KemPharm, Inc. Receives Notice of Allowance for Novel Pain Drug Candidate, KP201
North Liberty, IA – April 3, 2013 – KemPharm, Inc, a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application entitled, "Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydrocodone, Prodrugs, Methods of Making and Use Thereof."KP201, recently designated b... 
Printer Friendly Version
02/14/13KemPharm Supports Recent FDA Recommendations for Hydrocodone-Containing Compounds and Abuse-Deterrent Opioids
"Opioid-based therapeutics manage pain very well, but safe-guards and technological enhancements are needed to mitigate a clear abuse risk," Travis C. Mickle, Ph.D. North Liberty, IA – February 14, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, offered its support for the recent Food and Drug Administration (FDA) recommendations to curtail the potential abuse of opioid-based therapeutics. In two se... 
Printer Friendly Version
01/07/13KemPharm, Inc Receives USAN Approval for Nonproprietary Name of Novel Pain Drug Candidate, KP201
Benzhydrocodone's Unique Physicochemical and Pharmacological Attributes Offer Potential to Reduce Abuse and Opioid-Induced ConstipationNorth Liberty, IA – January 7, 2013 – KemPharm, Inc, a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that the United States Adopted Name (USAN) Council approved the use of the nonproprietary name, "benzhydrocodone", for its lead pain candidate, KP201. KP201 is in developmen... 
Printer Friendly Version
01/02/13KemPharm, Inc. to Present at Biotech Showcase™ 2013
North Liberty, IA – January 2, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that president and CEO, Travis Mickle, Ph.D. will present at the Biotech Showcase™ 2013 Conference being held in San Francisco January 7-9, 2013. Among the topics to be discussed, Dr. Mickle will provide an overview of KP201 the company's opioid-based drug candidate in development for the treatment of acut... 
Printer Friendly Version